Partnering Meeting Bio€quity Europe
Meet the Cellestia team at the Bio€quity Europe meeting (May 20-21, 2019) in Barcelona.
American Association for Cancer Research Meeting
Cellestia selected for an oral presentation on CB-103 by Dr. Raj Lehal, Chief Scientific Officer, at the Preclinical Drug Development session of the American Association for Cancer Research Meeting (Atlanta, March 29–April 3).
IND accepted by the FDA
On Feb. 4th, Cellestia received the green light from the FDA for its Investigational New Drug Application (IND). The FDA completed its review, and concluded that Cellestia can proceed with its clinical investigation of CB-103 in tumors driven by an oncogenic NOTCH signaling pathway.